Clinical features and treatment options for obstructive hypertrophic cardiomyopathy in women

Hypertrophic cardiomyopathy (HCM) is a genetically determined disease associated with the presence of mutations in the genes encoding the synthesis of myocardial contractile proteins. The presence of obstruction in the LVL is a powerful predictor of adverse outcomes and serves as an indication for surgical treatment. One of the frequent “masks” that patients with HCMP come with is “acute coronary syndrome” or “heart defect”. Patient O., 43 years old, maintained a good tolerance to physical exertion for a long time. Has 2 children. Pregnancies proceeded without pathology from the cardiovascular system. Mild arterial hypertension was registered after the second birth. In August 2017, the patient was hospitalized with a diagnosis of ACS, diagnostic coronary angiography was performed: the coronary arteries are not changed. During auscultation, systolic noise was heard over the precardial region. Previously, noises were detected. On an echocardiogram, an obstructive variant of HCMP with a gradient of 150 mmHg was diagnosed. Given the high gradient of LVL obstruction, the patient underwent selective alcohol ablation. After alcohol ablation, there was a high gradient in VTLJ – 96 mmHg. Cardialgia and shortness of breath persisted. No cardiac arrhythmias were recorded. In August 2019, the patient underwent an extended myoectomy with good effect. At control examinations a year after myoectomy: the pressure gradient on the AoC is 13 mmHg, VTLJ is 11 mmHg. This example illustrates the need to include HCMP in the circle of differential diagnosis when examining a young patient with chest pain, especially in combination with heart murmurs. Echocardiography with Doppler examination is a simple and affordable diagnostic method. The alcohol septal ablation performed was ineffective, and the extended myoectomy had a good hemodynamic and clinical effect and may be the method of choice of therapy in these patients. The peculiarity of this case is the manifestation of the disease at the age of 43, during two pregnancies without clinical manifestations of pathology of the cardiovascular system.

1. Alieva AM, Almazova II, Reznik EV, Pinchuk TV, Baykova IE, Kislyakov VA et al. Hypertrophic cardiomyopathy: a modern view of the problem. Cardiosomatics. 2020;11(1):39–45. (In Russ.) https://doi.org/10.26442/22217185.2020.1.200116.

2. Engel TR. Diagnosis of Hypertrophic Cardiomyopathy: Who Is in Charge Here-The Physician or the Computer? J Am Coll Cardiol. 2020;75(7):734–735. https://doi.org/10.1016/j.jacc.2019.12.028.

3. Jaaskelainen P, Vangipurapu J, Raivo J, Kuulasmaa T, Helio T, Aalto-Setala K et al. Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy. ESC Heart Fail. 2019;6(2):436–445. https://doi.org/10.1002/ehf2.12420.

4. Sukhacheva TV, Serov RA, Bockeria LA. Hypertrophic cardiomyopathy. Cardiomyocyte ultrastructure, the specific or stereotypic signs. Arkhiv Patologii. 2019;81(6):5–15. (In Russ.) https://doi.org/10.17116/patol2019810615.

5. Krylova NS, Kovalevskaya EA, Poteshkina NG, Mershina EA, Sinitsyn VE, Sonicheva NA, Monserrat L. Pulse reduction in management of hypertrophic cardiomyopathy (two clinical cases).russian Journal of Cardiology. 2017;22(12):104–112. (In Russ.) https://doi.org/10.15829/1560-40712017-12-104-112.

6. Rudomanova VV, Gordeeva SV, Alekseeva EV, Ivanchura GS. Hypertrophic cardiomyopathy. Scientific Bulletin of Kuban Healthcare. 2018;(2):51–67. (In Russ.) Available at: https://vestnik.kkb2-kuban.ru/article/448.

7. Baibolova MK, Trusheva KS, Toktarbayeva AA. Genetic aspects, clinical manifestations, diagnostics and modern approaches to the treatment of hypertrophic cardiomyopathy. Problems of Modern Science and Education. 2018;(2):44–54. (In Russ.)

8. Available at: https://www.elibrary.ru/ymfmqc. 8. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta-cardiac myosin heavy chain gene missense mutation. Сell. 1990;62(5):999–1006. https://doi.org/10.1016/0092-8674(90)90274-i.

9. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227–2232. https://doi.org/10.1161/01.CIR.0000066323.15244.54.

10. García-Castro M, Coto E, Reguero Jr, Berrazueta Jr, Alvarez V, Alonso B et al. Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2009;62(1):48–56. https://doi.org/10.1016/s1885-5857(09)71513-0.

11. Fidzianska A, Bilinska ZT, Walczak E, Witkowski A, Chojnowska L. Autophagy in transition from hypertrophic cardiomyopathy to heart failure. J Electron Microsc (Tokyo). 2010;59(2):181–183. https://doi.org/10.1093/jmicro/dfp048.

12. Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019;9(Suppl2):388–S415. https://doi.org/10.21037/Cdt.2019.02.01.

13. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history. Circ Res. 2011;108(6):743–750. https://doi.org/10.1161/CIRCRESAHA.110.223834.

14. Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: Molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15(2):158–170. https://doi.org/10.1016/j.jmoldx.2012.09.002.

15. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19(2):192–203. https://doi.org/10.1038/gim.2016.90.

16. Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter S. et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880–888. https://doi.org/10.1038/gim.2014.205.

17. Ageenkova OA. Clinical case of hypertrophic cardiomyopathy in a pregnant woman. Modern Problems of Science and Education. 2018;(2):17. (In Russ.) Available at: https://science-education.ru/ru/article/view?id=27460.

18. Fumagalli C, De Gregorio MG, Zampieri M, Fedele E, Tomberli A, Chiriatti C et al. Targeted Medical Therapies for Hypertrophic Cardiomyopathy. Curr Cardiol Rep. 2020;22(2):10. https://doi.org/10.1007/s11886-020-1258-x.

19. Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228–240. https://doi.org/10.1002/ejhf.1715.

20. Tuleutayev RM, Enin EA, Sydykov ET, Abzaliev KB. Surgical treatment of hypertrophic cardiomyopathy. Bulletin of the Almaty State Institute of Advanced Medical Training. 2017;(3):48–54. (In Russ.) Available at: https://www.elibrary.ru/ylpwjo.

21. Lysenko AV, Akselrod BA, Lednev PV, Salagaev GI, Grabuzdov AM, Belov YuV. Surgical treatment of obstructive hypertrophic cardiomyopathy in a patient with previous kidney transplantation. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2020;13(1):64–67. (In Russ.) Available at: https://www.elibrary.ru/ordhzj.

22. Velieva LM, Dzhordzhykiya RK. Obstructive hypertrophic cardiomyopathy: historical aspects and modern methods of treatment (review). Bulletin of Contemporary Clinical Medicine. 2020;13(2):55–62. (In Russ.) https://doi.org/10.20969/VSKM.2020.13(2).55-62.

23. Komagamine M, Nishinaka T, Ichihara Y, Saito S, Niinami H. Long-Term Clinical Outcomes of Cardiac Surgery for Kidney Transplant Patients. Ann Thorac Cardiovasc Surg. 2020;26(2):84–87. https://doi.org/10.5761/atcs.oa.19-00192.

24. Lysenko AV, Lednev PV, Salagaev GI, Sinyavin GV, Barinov EV, Grabuzdov AM, Belov YuV. The modern view on the diagnosis and treatment of hypertrophic cardiomyopathy. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2019;12(1):38–44. (In Russ.) https://doi.org/10.17116/kardio20191201138.

25. Sinitsyn VE, Mershina EA, Pershina ES, Blagova OV. A rare case of non-coronary ischemic myocardial lesion in hypertrophic cardiomyopathy (HCMP). Poliklinika. 2014;(3-1):16–18. (In Russ.) Available at: https://www.elibrary.ru/sybfyh.

26. Shloydo EA, Sukhov VK. Alcohol ablation of interventricular septum and coronary stenting with a combination of obstructive hypertrophic cardiomyopathy and coronary artery disease. Bulletin of Almazov Federal Heart, Blood and Endocrinology Centre. 2011;(5):89–93. (In Russ.) Available at: https://www.elibrary.ru/owghpf.

27. Khitrova ME, Bockeria LA, Berseneva MI, Plavinskiy SL, Avdeeva MV. Metaanalysis of results the surgical treatment hypertrophic obstructive cardiomyopathy. Creative Cardiology. 2017;11(4):337–347. (In Russ.) https://doi.org/10.24022/1997-3187-2017-11-4-337-347.

28. Kashtanov MG, Chernyshev SD, Kardapoltsev LV, Berdnikov SV, Idov EM. Ethanol septal ablation in the treatment of obstructive hypertrophic cardiomyopathy: selection of patients and the rationality of its use. Patologiya Krovoobrashcheniya i Kardiokhirurgiya. 2017;21(1):104–116. (In Russ.) https://doi.org/10.21688/1681-3472-2017-1-104-116.

29. Trifonov MO, Volkova SYu. Diagnosis of hypertrophic cardiomyopathy in a modern hospital. Universitetskaya Meditsina Urala. 2017;3(2):100–101. (In Russ.) Available at: https://www.elibrary.ru/yucbex

30. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–255. https://doi.org/10.1016/S0140-6736(12)60397-3.

31. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027–1035. https://doi.org/10.1056/NEJMoa025050.